A newly published cache of CRLs includes six novel oncology drugs.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The group is persevering with Granite, but funds might be hard to come by.
First-in-human trial initiations reveal four KRAS assets.
For $850m up front Roche gets to challenge Pfizer.
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.